Investigation Report on China Idarubicin Market, 2010-2019

The exact cause of leukemia is yet to be identified with interior decoration pollution, ionizing radiation, drug...
Reference: 1508304
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
8/18/2015
Pages
30
Version:
2010
Charts:
30
Language
  • English
  • Chinese
Format
License

Description

The exact cause of leukemia is yet to be identified with interior decoration pollution, ionizing radiation, drug contamination and virus infection all being the suspect. The increasing incidence of leukemia is growing in China and the number of new cases reaches 40000 each year, among which over 85% belongs to acute leukemia.
Developed by Italian Arca-mone, idarubicin is an analog of daunorubicin with higher fat solubility. Its main metabolite works by preventing DNA unwinding. In preliminary studies, idarubicin turns out to be more effective and less toxic than DNR and DXR in treating L1210 leukemia, P338 leukemia and Gross leukemia. Since 1988, Japan has conducted clinical research on acute leukemia.
As an anti-mitosiss agent, idarubicin is used in the first line treatment of acute nonlymphoblastic leukemia (ANLL) relapse remission and the second line treatment of acute lymphoblastic leukemia (ALL).
According to CRI's market survey, idarubicin enjoys an increasing demand in China with sales value rising from about CNY 14 million in 2005 to over CNY 80 million in 2014 and CAGR during the period of 2010-2014 reaching 22%. And Pfizer Hisun Pharmaceutical Co., Ltd, Pharmacia&Upjohn (IT), Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd, Pfizer Inc. (IT) and Nerviano Medical Science S.r.l. (IT) occupy the market, among which Pfizer Hisun Pharmaceutical Co., Ltd had the largest market share of over 40% for sales value in 2014.
Research has shown that autologus hematopoietic stem cell transplantation (HSCT) is an effective way to treat ALL. As idarubicin is included in autologus HSCT, its future demand is expected to be great.

Readers can get at least the following information through this report:
-market size of idarubicin in China
-competitive landscape of idarubicin market in China
-price of idarubicin made by different enterprises in China
-market outlook of idarubicin in China

The author suggests the following groups of people purchase this report:
- manufacturers of antileukemic agents
-investors/research institutions interested in Chinese medicine market
--any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1 Related Concepts of Idarubicin
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Idarubicin in China
2.1 Patent and Approval Information of Idarubicin in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Idarubicin Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Idarubicin Manufacturers in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Idarubicin in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Idarubicin in Chinese Hospitals in 2014
6.1 Pfizer Hisun Pharmaceutical Co., Ltd
6.2 Pharmacia&Upjohn (Italy)
6.3 Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd
6.4 Pfizer Inc. (Italy)

7 Major Manufacturers of Idarubicin in Chinese Market, 2010-2014
7.1 Pfizer Hisun Pharmaceutical Co., Ltd
7.2 Pharmacia&Upjohn (Italy)
7.3 Pfizer Inc. (Iyaly)
7.4 Nerviano Medical Science S.r.l. (Italy)

8 Market Outlook of Idarubicin in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Table of Selected Charts

Chart Approval Information of Idarubicin in China
Chart Idarubicin Sales in China
Chart Sales Value of Idarubicin in China, 2010-2014
Chart Sales Value of Idarubicin in Some Regions in China, 2010-2014
Chart Sales Volume of Idarubicin in China, 2010-2014
Chart Sales Volume of Idarubicin in Some Regions in China, 2010-2014
Chart Market Share of TOP5 Idarubicin Enterprises for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Made by Pfizer Hisun in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Made by Pharmacia&Upjohn (IT) in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Made by Pharmacia&Upjohn (Suzhou) in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Injection in China, 2010-2014
Chart Sales Value and Market Share of Idarubicin Capsule in China, 2010-2014
Chart Price of Idarubicin Made by Pfizer Hisun Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Pharmacia&Upjohn (IT) in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Pharmacia&Upjohn (Suzhou) in Some Chinese Cities in 2014
Chart Price of Idarubicin Made by Pfizer (IT) in Some Chinese Cities in 2014

Chart Price of Idarubicin Made by Nerviano Medical Science S.r.l. (IT) in Some Chinese Cities in 2014

Scroll